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Abstract
There are many drug interactions and to know every single interaction is impossible. In
Uganda, a country located in East Africa, patients often do not get a patient informa-
tion leaflet when a physician prescribes drugs because they only get the drugs without
packaging and information inside. Even in developed countries many poeple die because
of drug interactions.
This work aims at developing a clinical decision support system for different kinds of
drug interactions: 1) drug-drug interaction, 2) drug-food interactions, 3) drug-condition
interactions and 4) drug-disease interactions. This system must be integrated into an
existing hospital information system called electronic Health Management Information
System (eHMIS).
In the first part of this thesis different kinds of clinical decision support systems are
described to find out which one is the best for eHMIS. The two different types are
knowledge-based and non knowledge-based systems.
The second part of this thesis, the data base of eHMIS is extended to have a full
knowledge base for the new module which contains drug-drug interactions, drug-food
interactions, drug-disease interactions as well as drug-condition interactions. Therefore
new tables were created and filled with data of several data bases with drug interactions.
The last part is about designing the clinical decision support system for drug interac-
tions with the knowledge base of eHMIS, including the implementation considering the
integration into the existing system. To know how health professionals in Uganda work
with an electronical health system as well as their other workflows was important. The
system now runs in a hospital in Kampala, the capital of Uganda and in a health center
level three in Mifumi, a village located in the east of the country.
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In most developing countries health information management is realized paper-based.
In Uganda, a country located in East-Africa, there is also the same situation but elec-
tronical systems were and will be implemented in hospitals and health professionals
currently get an induction into it. The paper-based system is comprised of data-set
formats and is called Health Management Information System (HMIS). However, with
a non-electronical HMIS it is time-consuming and more expensive, because more health
professionals are needed. There can be also errors while recording data and transferring
it to paper forms. For example a health worker is writing 57 kilograms for body weight
instead of 75 kg. The body weight can affect dosages of medication so it is important
to know the correct weight. To avoid such errors Electronic Health Record (EHR) can
assist health professionals recording patient data correctly by flag abnormal values[37]
or provide lists of possible explanations for those abnormalities[25].
To support physicians and other health workers in their decisions an eletronical health
management information system is a good choice. Such an information system has
several advantages: 1) improve quality and convenience of patient care, 2) increase
patient participation in their care, 3) improve accurace of diagnoses and health outcomes,
4) improve care coordination, 5) increase practice efficiencies and cost saving[37].
In Uganda an electronical version of a HMIS is called eHMIS[19]. eHMIS were de-
veloped by Dr. Simon Ndira as part of his PhD. programme. It provides modules for
several wards in a hospital like Mengo Hospital in Kampala but there is no decision
support system which shows alerts if two drugs a patient is taken interact. Such in-
teractions can causes fatal consequences like death [16]. An underestimated problem is
also a drug-to-food intaction like antibiotic and milk [21]. Especially a hospitals Outpa-
tient department (OPD) has a high workload with patients and medication. A clinical
decision support systems may help doctors to improve treatments of patients through
assisting them in their decision making. You can also support patients directly with
free guides like A Guide from the National Consumers League and U.S. Food and Drug
Administration[27]. But people in delevoping countries do not have good internet access
or the education is too low to know about guides or articles. That is why health profes-
sionals need to support patients by saying how to use medication and explain possible
interactions.
In developing countries further problems like missing technical resources or power
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breakdowns complicate the deployment and usage of a drug-to-X system which alerts
physicians if there is a bad interaction.
Risks with drugs do not mostly result of individually misconduct but of suboptimal
procedures of medication processes. Therefore it is important, all health professionals
need to work together to minimize risks[42].
Figure 1.1: The swiss cheese model by Reason shows, how a medication error can emerge if safety barries
fail.
1.2 Types of drug interactions with examples
The idea was to implement a system for drug interactions for different areas, which are
described later in the following sections. Generally a drug interaction means a situation
in which an ingredient or a substance influences the activity of another substance. There
are three possible actions: first a synergestic (the effect of a drug increases) or an
antagonistic (drug’s effect decreases) or a substance of a drug produces a new effect.
1.2.1 Drug-drug interactions
A drug to drug interaction occurs if a person is taking more than one drug and one or
more of the taken drugs interact with a substance of another taken drug. Most adverse
drug to drug interactions are either pharmacodynamic or pharmacokinetic in nature.
11
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To describe these it goes beyond the scope of this thesis. The following list shows some
drug-drug interactions[8][31][6]:
• Pain relievers
– Tylenol (acetaminophen) and Rifadin, Rimactane (antibiotics ri-
fampin):
Gets in the way of how the liver processes acetaminophen and increases the
risk of liver problems when taking acetaminophen.
– Aspirin and Diabinese (chlorpropamide):
Aspirin increases the bloodsugar-lowering effects of diabetes medicines.
– Aspirin and Anti-seizure drugs like Dilantin and valproic acid like
Depakene:
Aspirin gets in the way of the anti-seizure drugs binding with proteins in the
blood and leads to increased anti-seizure drug levels in your blood.
– Aspirin and Ibuprofen 200:
Ibuprofen may reduce the effectiveness of aspirin if you are taking it to prevent
heart attacks or strokes. This interacion also can developing gastrointestinal
ulcers and bleeding.
– Paracetamol and Emla (lodicaine/prilocaine topical):
”Prilocaine topical can cause a condition called methemoglobinemia that re-
duces the oxygen-carrying capacity of the blood to different organs, and com-
bining the medication with acetaminophen may increase the risk. Infants and
patients with certain conditions such as glucose-6-phosphate dehydrogenase
deficiency or anemia are more likely to develop this condition. You should
seek immediate medical attention if you notice signs and symptoms such as
a gray discoloration of the skin, mouth, or nail bed; nausea; headache; dizzi-
ness; lightheadedness; fatigue; shortness of breath; rapid or shallow breathing;
a rapid heartbeat; anxiety; and confusion.“
• Antihistamines
– Dimetapp Allergy (brompheniramine) and Qsymia (phentermine/
topiramate):
Topiramate are for increasing the body temperature and decreasing sweating.
Combined with a brompheniramine like Dimetapp the effects can be greater.
Other adverse effects could be heat stroke and hospitalization in some people.
Also dizziness, lightheadedness or drowsiness may occur.
– Epiklor (potassium chloride) and Dramamine (dimenhydrinate):
”The following interaction applies only if you are taking potassium in a solid
formulation (i.e., tablet or capsule swallowed whole): Talk to your doctor be-
fore using potassium oral tablets or capsules together with CS2. Depending
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on the dose of CS2 and your overall physical health, combining these medi-
cations may increase the irritant effects of potassium on your stomach and
upper intestine. This can rarely result in ulcers, bleeding, and other gastroin-
testinal injury.“ Also occur can abdominal pain, bloating, sudden diziness or
lightheadedness, nausea, vomiting (with blood), loss of appetite and much
more.
• Descongestants
– Sudafed Congestion (pseudoephedrine) and Atapryl (selegiline):
”Using selegiline together with pseudoephedrine is not recommended. Com-
bining these medications can cause dangerously high blood pressure and even
death. You may use pseudoephedrine only after you have been off selegiline
for at least 14 days. You should seek immediate medical attention if you expe-
rience sudden and severe headache, blurred vision, confusion, seizures, chest
pain, nausea or vomiting, sudden numbness or weakness (especially on one
side of the body), speech difficulties, fever, sweating, lightheadedness, and/or
fainting during treatment with selegiline, as these may be signs and symptoms
of excessively high blood pressure.“
– Contact Cold and Sore Throat (pseudophedrine) and Cymbalta
(duloxetine):
”Combining these medications can increase the risk of a rare but serious con-
dition called the serotonin syndrome, which may include symptoms such as
confusion, hallucination, seizure, extreme changes in blood pressure, increased
heart rate, fever, excessive sweating, shivering or shaking, blurred vision,
muscle spasm or stiffness, tremor, incoordination, stomach cramp, nausea,
vomiting, and diarrhea. You should contact your doctor immediately if you
experience these symptoms while taking the medications. It is important to
tell your doctor about all other medications you use, including vitamins and
herbs.“
• Cough Medicines
– Delsym (dextromethorphan) and Celexa (citalopram):
”Combining these medications can increase the risk of a rare but serious con-
dition called the serotonin syndrome, which may include symptoms such as
confusion, hallucination, seizure, extreme changes in blood pressure, increased
heart rate, fever, excessive sweating, shivering or shaking, blurred vision,
muscle spasm or stiffness, tremor, incoordination, stomach cramp, nausea,
vomiting, and diarrhea. You should contact your doctor immediately if you
experience these symptoms while taking the medications. It is important to





A drug to food interaction occurs if a person is eating certain food and taking one or
more drugs. Thereby, it is possible that the effect increases, decreases or an unexpected
effect appears. The list below shows some of them[8][31][6]:
• Grapefruit juice and certain blood pressure-lowering drugs:
”Grapefruit juice is often mentioned as a product that can interact negatively with
drugs, but the actual number of drugs the juice can interact with is less well-known.
Grapefruit juice shouldn’t be taken with certain blood pressure-lowering drugs or cy-
closporine for the prevention of organ transplant rejection. That’s because grape-
fruit juice can cause higher levels of those medicines in your body, making it more
likely that you will have side effects from the medicine. The juice can also inter-
act to cause higher blood levels of the anti-anxiety medicine Buspar (buspirone);
the anti-malaria drugs Quinerva or Quinite (quinine); and Halcion (triazolam), a
medication used to treat insomnia.“
• Alcohol and drugs:
The patient information leaflet and every physician says that alcohol can influences
the effects of drugs. Trinking alcohol and alcohol abuse may change the amount
of enzymes in the liver, above all the enzyme CYP2E1. ”Cytochrome P450 2E1
(abbreviated CYP2E1, EC 1.14.13.n7), a member of the cytochrome P450 mixed-
function oxidase system, is involved in the metabolism of xenobiotics in the body.
In humans, the CYP2E1 enzyme is encoded by the CYP2E1 gene.[1] While it is in-
volved in the oxidative metabolism of a small range of substrates (mostly small polar
molecules), there are many important drug interactions mediated by CYP2E1.“ [?]
• Vitamin E and blood-thinning medication:
”Taking vitamin E with a blood-thinning medication such as Coumadin can increase
anti-clotting activity and may cause an increased risk of bleeding.“
1.2.3 Drug-condition interactions
If a person is in a specific condition, for example pregnant or underweight. It may occur
when an existing medical condition makes certain drugs potentially harmful.
”Animal studies failed to reveal embryotoxicity or teratogenicity, although maternal
toxicity in some animal studies resulted in increased incidence of abortion. There are
no controlled data in human pregnancy. However, ciprofloxacin has been shown to dis-
tribute into amniotic fluid. Concentrations reported were 57% (at 2 to 4 hours post
dose) to 1000% (at 10 to 12 hours post dose) of that found in maternal serum. A re-
view by the Teratogen Information System concluded that a substantial risk is unlikely;
however, there were insufficient data to state that there is no risk. Cartilage damage
and arthropathies associated with ciprofloxacin have been reported in immature animals
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of various species, giving rise to concern over its possible toxic effects on human fetal
bone formation. Because safer alternatives are generally available, some experts consider
ciprofloxacin contraindicated during pregnancy, especially during the first trimester. Of
549 cases reported by the European Network of Teratology Information Services involv-
ing fluoroquinolone exposure (including ciprofloxacin), congenital malformations were
reported in 4.8%; however, this was not higher than the background rate. In the U.S.
Michigan Medicaid surveillance study of 229,101 pregnancies, major birth defects were
reported in 3 of 132 exposed neonates. An association between ciprofloxacin and congen-
ital defects is not supported by these data. Berkovitch and colleagues reviewed 35 preg-
nancies in women who received norfloxacin or ciprofloxacin during the first trimester
for urinary tract infection. No malformations were observed among the infants of these
women. There were no joint problems or walking delays, and when compared to non-
exposed infants, there was no apparent difference in the acquisition of milestones. In
mass casualty settings after release of biological weapons, the Working Group on Civil-
ian Biodefense has recommended ciprofloxacin as the drug of choice for postexposure
prophylaxis and treatment of anthrax, and as an alternative for tularemia and plague.
The risk is outweighed by the high fatality rates from these infections. FDA pregnancy
category C: Animal reproduction studies have shown an adverse effect on the fetus and
there are no adequate and well-controlled studies in humans, but potential benefits may
warrant use of the drug in pregnant women despite potential risks.“
1.2.4 Drug-disease interactions
This happen when a prescription or over-the-counter medication interacts, or inter-
feres, with a disease or condition that a patient have. For example Non-steroidal anti-
inﬄammatory drugs (NSAID) may have an effect to the blood pressure. People with
high blood pressure should not take these drugs.
1.3 Goal of this Work
Extending an existing hospital information system the present thesis following six goals:
1) extent the existing database to have a full knowledge base for a drug interaction
system, 2) implement a clinical decision support system for different drug interactions,
3) integrate the new module into eHMIS, 4) studying if such a decision support system
is useful and health worker will accept it, 5) assist health professionals in their work by
alerting if there is a drug interaction, 6) help patients to avoid drug-food interactions.
1.4 Structure of the Thesis
This thesis is divided in seven chapters and an appendix. After the introduction part in
this chapter, the second chapter starts with a describtion of the environment, Uganda’s
15
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health system and infrastructure. Futhermore, it describes health facilities in which the
system is used, both the non-electronical and electronical health management informa-
tion system.
The third chapter is about the fundamentals of clinical decision support. How such
a system works is the basic explanation of this chapter. It illustrates also a common
possibility of a structure of a clinical decision support system, for knowledge- and non-
knowledge based.
Chapter four is about how the CDSS was designed and implemented. It illustrates
the knowledge base and the written modules of drug interactions. This chapter also
contains the technical environment with models and schemes.
The text of the fith chapter lists the results of impolementing the approach of a clinical
decision support system for drug interactions.
Chapter six discusses these results and gives an outlook on possible future extensions
and improvements.
Finally the appendix contains written functions and the bibliography.
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The clinical decision support system was integrated into eHMIS [19]. eHMIS is already
implemented in some hospitals in Uganda, for example at Mengo Hospital, located in
Kampala, the capital of Uganda. It is also installed at Mifumi Health Centre but in
another version. Mifumi is a small village based 27km from Tororo town, in Eastern
Uganda. Because health care systems and infrastructures of developing countries can
differ from systems of developed countries this chapter will deliver an insight into Ugan-
das health care system and infrastructure. Furthermore a description of Mengo Hospital
and eHMIS will be given.
2.1 Ugandas’s health system and infrastructure
According to the Ministry of Health (MoH)[24] and Uganda Bureau Of Statistics (UBOS)[39]
the health structure of Uganda can be described as follows [28]: There are a total number
of 11,130 health facilities in Uganda. 62.3% are owned by the Goverment of Uganda,
19.2% belongs to the private sector and Private Not For Profit (PNFP) own 18.4%.
Currently there are two National Referral Hospitals (NRH), twelve Regional Referral
Hospitals (RRH) and 135 general hospitals, 56 PNFP hospitals and 9 Private Hospitals
(PHP) as well as 1552 health center. Government hospitals are classified by the services
they provide. There are:
• NRH. In Uganda there are 2 NRHs: Butabikahospital in Kampala as well as
Mulago hospital, also in Kampala. These national refferal hospitals provide both
teaching services and health research and specialized services.
• RRH provide specialist services like radiology, high level surgical, psychiatric and
more.
• General/District Hospitals provide a large output for outpatient and inpatient
services and als provide support supevision to lower level health facilities.
Hospitals are at the top of the healthcare chain. In national referral and regional refer-
ral hospitals there are specialits available. District and general hospitals are staffed by
general doctors. They are supposed to provide at least the following services: medicine,
surgery, paediatrics, obstetrics and gynaecology, dentistry, anaesthesia, radiology, clini-
cal laboratory and community health.
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The other categories of health facilities are the Health Centers. They are devided in
three grades:
• Health centre 2 (Enrolled Comprehensive Nurse) (HC II): According to the Ugan-
dan government’s health policy, every parish is supposed to have one of these
centres. A health centre II facility, serving a few thousand people, should be able
to treat common diseases like malaria. It is supposed to be led by an enrolled nurse,
working with a midwife, It runs an outpatient clinic, treating common diseases and
offering antenatal care.
• Health centre 3 (Cinical Officer) (HC III): This facility should be found in every
subcounty in Uganda. These centres should have about 18 staff, led by a senior
clinical officer, It should also have a functioning laboratory.
• General/District Hospital and Health centre 4 (Medical Officer) (HC IV): This
level of health facility serves a county. In addition to services found at health
centre III, it should have wards for men, women, and children and should be able
to admit patients. It should have a senior medical officer and another doctor as
well as a theatre for carrying out emergency operations.
2.1.1 Mengo Hospital
Kampala district has an estimated population of 1.72 million [36]. Kampala district
provides 5 hospitals and around 200 health units [28], including Mengo Hospital. Mengo
Hospital, also known as Namirembe Hospital, is a Non-Government Hospital. Services
provided are: antenatal, counselling and come-care, dental, eye, laboratory and occupa-
tional therapy.
2.1.2 Mifumi Health Center
The Mifumi Health Center is a HC III, located 27km from Tororo town in Mifumi,
Eastern Uganda. With a hinterland of around 80,000 people, it provides appropriate
health care services with a focus on enhancing quality of life and protecting the rights
of vulnerable people. Opened in 2001 the main diseases encountered are: Malaria, Mal-
nutrition, HIV, Schistosomiasis and others. There is also a offer for health education,
HIV screening and Prevention of Mother to Child Transmission of HIV.
2.2 Health Management Information System: HMIS
The HMIS was released by the Ministry of Health, Replublic of Uganda. It’s objective
is to provide a routine based system to collect data about the health system. HMIS has
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been designed for use of all units and districts for planning and improving the health
system of Uganda by evaluating the healthcare system [19].
HMIS consists exclusively of paper-based database formats for all levels of the health
system, i.e. forms for the health units, the health sub-districts, the districts and the
Ministry of Health Headquarters. Reports are delivered form the lowest level (health
units) up to the next level on a monthly basis. The list below shows which data are
collected [19]:
• Morbidity data from outpatient departments: These are among others: Mother
and Child Health and Family Planning activities, essential drugs, vaccines and
contraceptive stock.
• Morbidity and mortality data from inpatient departments: Referrals, number of
admissions and deaths by diagnosis, utilization of special services, etc.
• Notifiable diseases
• Epidemiological surveillance reports
The last version implemented both formal and on-the-job training for health workers.
2.3 Electronical version: eHMIS and its platform
As in the above section stated before HMIS documentation was exclusively paper-based.
Hence Dr. Simon Peter Ndira designed and developed an electronical version of HMIS
called eHMIS (electronical Health Management Information System) as a part of his
doctoral thesis. eHMIS enables hospital staff to manage patient data electronically in
the health environment[19]. Before the project for a decision suport system started,
eHMIS provided several modules for managing patient data for different wards like den-
tal, optics, laboratory or ophthalmology. Other functions like administrate a user profile
or a ticketing-system is also available. Users with required permissions are able to carry
out functions for system maintenance like for example database dumps. Also permission
rights for different users can be managed as well as for user groups.
To run eHMIS, which is browser-based, you need a so called LAMP environment.
LAMP stands for Linux, Apache, MySQL and PHP. In both health facilities Mengo
Hospital and Mifumi Health Center the network structure is made up by a client-server-
technology. At Mengo Hospital the server is located in the information technology
department and at Mifumi Health Center in the pharmacy. Laptops for working are
available in every room where they needed.
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3.1 Fundamentals of Clinical Decision Support Systems
Deduced from expert systems research early Clinical Decision Support (CDS) were de-
signed by its developers with rules that would allow computers to “think” like health
professionals when confronted with a patient [32].
CDSs provide both expert clinicians and other persons with knowledge and person-
specific information. This information is filtered and presented at appropriate times to
improve health and health care [14].
To assist health professionals at the point of care is the main purpose of modern CDS
[2]. Clinicians work with a Clinical Decision Support System (CDSS) which should help
them to determine diagnosis, analysis or show alerts for specific patient data. This
means such systems should not play the role as a physician but support them.
3.2 Types of Clinical Decision Support Systems
To support clinical decisions there are variant types of clinical decision support sys-
tems. Even systems like Medline[20] can assist health professionals in their decisions.
Generally, first decision support systems have supported retrospective analyses of fin-
cancial and administrative data[29]. Lately, complex data mining approaches for similar
retrospective analyses of both administrative and clinical data have been proposed[4].
Despite using these retrospective approaches to develop guidelines or other systems to
guide decision making at point of care, such retrospective analyses are not usually con-
sidered to be CDSS. To know this is important because suppliers often will provide their
products including decision support capabilities, but their systems are not designed to
assist clinicians at the point of care[2]. Because the interest of CDSSs increasing, vendors
will integrate such types of CDS into their systems.
In obedience to a framework of Metzger and her colleagues[30][22], their CDSS using
several dimensions which differ among themselves in the timing at the point it provide
the service (before, during, or after the clinical decision is made). Another point the
dimensions differ is how active or passive the system assits physicians and other health
professionals (alerts on the fly or passively responds to the physician input or patient-
specific information). Such systems also differ in wether the information provided is gen-
eral or speciality-based. There are also noncommercials computerbased patient record
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systems which incorporate CDSSs and vendors are beginning to integrate clinical deci-
sion support systems into their computer based patient records and physician order entry
systems. An important categorization scheme for clinical decision support systems is, if
they are knowledge-based clinical decision support systems or non-knowledge based sys-
tems that employ machine learning and/or other statistical pattern recognition CDSS[2].
The focus in the thesis is on the knowledge-based systems but other approaches will also
be discussed.
3.2.1 Knowledge-based CDSS
Like above described, various knowledge-based CDSS which are used today originated
out of past expert system’s research, which were built to simulate human thinking
[23][35]. First CDSS were developed for diagnostic decision support. Since the last
twenty years the intent of these CDSSs was to assist health workers and not to simulate
an expert’s decision[2]. The system was expected to provide information for the user,
rather than to come up with ”the answer“, as was the goal of earlier expert systems.
To filter that information and find out errornous or useless information was the user’s
purpose. With such an approach the user can be active and interact with the system,
rather than just be a passive recipient of the ouput. Such an interaction is important in
setting appropriate expectations for the way the system will be used.
A knowledge-based clinical decision support system consists of three parts:
• A knowledge base which contains for example compiled clinical information on
diagnoses, rules, associations of compiled data, drug interactions et cetera. A rule
for drug interactions could be a IF...THEN rule, for example IF drug A is taken
AND drug B is taken THEN show message to the user. In this case, the rule is
designed to prevent that a patient will take two or more drugs which can interact,
e.g. Brivudin (Zostex R©) and 5-Flouropyrimidine and 5-Flourouracil (for therapy
for breast carcinoma). Another example of knowledge bases might be a blood
test[2]: IF a new order is placed for a particular blood test that tends to change
very slowly, AND IF that blood test was ordered within the previous 48 hours,
THEN alert the physician. In this case, the rule is designed to prevent duplicate
test ordering.
• An inference enginge combines that knowledge with patient-specific information.
It contains formulas for combining rules or associations in the knowledge base with
actual patient data.
• Last but not least, there has to be a mechnism for the communication. The
patient data need to get into the system and the system needs to bring the output
to the user who will make the actual decision. In some systems the user needs
to type in the data directly. In most cases a CDSS in inefrated into an electronic
medical record system, the data are already in electronic form and come from the
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computer-based patient record, where they were entered by health professionals,
from laboratory or other hospital wards. One way to assist the pysician is to
alert the information on the fly. Other methods are sending a message after the
initial order was entered if the altert was triggered. Also possible is a system of
email and wireless notification to send messages. Such an approach is already
employed[17][34].
In a hospital or health center there are a lot of decisions where a system can assist
health professionals. CDSSs have been developed for such situations. One example
above describes a situation where a phycisian is prescribing two drugs which interact.
Systems like this have been developed to provide a list of potential diagnoses to the users.
Entered by the clinician or data already in the Electronic Medical Record (EMR), the
system might start with the patient’s signs and symptoms. The knowledge base of
the decision support system contains information about diseases and their signs and
symptoms. Now, the inference enginge maps these information to patient signs and
symptomps and eventualls provide some information to the physician to assist his or
her decision. It is important that a physician who knows the patient better than the
computer system he or she uses, to eliminate some of the choices.
A system which provide support for medication orders is a good way to avoid medical
errors, which are a major cause of death[16][10]. There are also CDSSs that are part of
Computerized Physician Order Entry (CPOE) systems. The imput for the system might
be the patient’s laboratory test results for the blood level of a prescribed medication.
The knowledge base might contain values for therapeutic and toxic blood concentrations
of the medication and rules on what to do when a toxic level of medication is reached.
If the medication level was too high, the ouput might be an alert to the physician[2].
3.2.2 Nonknowledge-based CDSS
Differently of knowledge-based clinical decision support systems, a form of artificial
intelligence, called machine learning, is used by nonknowledge-based CDSSs in form
of neural networks or genetic algorithms, id est, computers learn from past experience
and/or find patterns in clinical data of an individual[41]. This two approaches are
explained in the following sections.
Artificial Neural Networks
Artificial neural networks (ANN) simulate human thinking and learn from examples[41]
and refer to the human brain. ANNs are spereated in two bigger fields[1]:
• Artificial neural networks which were modelled to understand easier the function-
ality of the human brain.
• Artificial neural networks to solve statistical problems in statistics, economics,
technology and many other fields.
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An ANN contains of several neurons. This neurons also called as units or nodes. Nodes
are for taking information of other units or the environment and transfer modified in-
formation to other nodes or to the environment. There are three different kinds of
neurons:
Figure 3.1: Schematic describtion of a neural network
Nodes on top of each other (for example the red output nodes) could be summarized
as layer.
The connection between units is called an edge, the strength of a connection is enun-
ciated as connection weight. The stronger the weight the bigger is the influence of a unit
to another. There are three weights:
• Positive weight means this weight has an exitatory influence.
• Negative weight says the influence is inhibitory.
• A weight of null implies that a neuron has no influence to another one.
The knowledge of a network is saved in their weights. Changes in weight means the
learning of a neural network. How a weight changes depends on the learning rule. The
input which a neuron gets from another unit depends of two values, that are multiplied
connected:
• Output (respectively activity level) of the sending unit
• Weight between two neurons
The stronger the activity level of the sending unit the highter is the weight between
two units, the bigger is the influence (input) to the receiving unit. There is no influence
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if one of the values euqals zero.
The whole input of a unit is called netinput which is defined through the inputfunc-
tion. The most wide spreaded function is a linear combination at which the netinput is
composed additive of the other inputs that ae neuron gets from other neurons. Figured
as formula:
inputij = aj · wij
i = he receiving unit and j the sending units
aj = the activity level of the sending unit j








Figure 3.2: Calculation of netinput
This structure bears some similarities to the knowledge-based decision support sys-
tems, but rather than having a knowledge base derived from the medical literature or
from an expert clinicians knowledge, the ANN analyzes the patterns in the patient data,
to derive the associations between the patients signs and symptoms and a diagnosis.
Many of the knowledge-based CDSSs cover a wide range of diseases. For instance, the
input may be the signs and symptoms exhibited by a patient and the output may be the
possible diseases the patient may have. Neural networks often focus on a more narrow
range of signs and symptoms, for instance, those associated with a single disease, such
as myocardial infarction[3].
If having a large amount of data, these systems can learn from examples when supplied
with known results[12]. The system will study this information, make guesses for the
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correct output, compare the guesses to the given results, find patterns that match the
input to the correct output, and adjust the weights of the connections between the
neurodes accordingly, in order, to produce the correct results. This iterative process
is known as training the artificial network. In the example with myocardial infarction,
for instance, the data including a variety of signs and symptoms from large numbers
of patients who are known to either have or not have a myocardial infarction can be
used to train the neural network. Once the network is trained, i.e., once the weighted
associations of signs and symptoms withthe diagnosis are determined, the system can
be used on new cases to determine if the patient has a myocardial infarction[2].
There are both advantages and disadvantages using ANNs. A big advantage is there
is no need for direct inputs of experts and the need of writing IF...THEN... rules are
dropped. Because of their dynamic nature ANNs can proccess incomplete data by infer-
ring what the data should be and can improve every time they are used. Also not needed
is a large database to make predictions about outcomes, but the more comprehensive
the training data set is, the more accurate the ANN is likely to be[12]. A disadvantage
is the time consuming proccess of training, because ANNs follow a statistical pattern
recognition approach to derive their formulas for weighting and combining data. The
results often not easily interpretable. Another problem is that the system could not
explain why it uses certain data the way it does, which can make the reliability and
accountability of these systems a concern[12].
There are studies which have shown, ANNs can predict which patients are at high
risk for cancer such as oral cancer[26]. Predicting outcomes for surgery recovery or liver
transplants are also possible with artificial neural networks as well as the analysis of
waveform of electrocardiogramss (ECGs) and electroencephalograms (EEGs)[1].
Genetic Algorithms
In the 1940s, John Holland developed Generic Algorithms (GA). GAs simulate the pro-
cess of natural evolution by Darwin which is about natural selection and surviving of
the fittest[41]. To understand a genetic algorithm in computer science it is important
to understand the organismic evolution. Just as species change to adapt to their envi-
ronment, GAs reproduce themselves in various recombinations in an effort to find a new
recombinant that is better adapted than its predecessors. In other words, without any
domain-specific knowledge, components of random sets of solutions to a problem are
evaluated, the best ones are kept and than recombined and mutated to form the next
set of possible solutions to be evaluated, and this continues until the proper solution
is discovered. The fitness function is used to determine which solutions are good and
which one should be eliminated. GAs are similar to neural networks in that they derive
their knowledge from patient data. Genetic algorithms have also been applied in health
care, but there are fewer examples of this type of CDSSs than those based on neural
networks. The following table shows the comparison of fundamental terms in biology
and computer science.
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Term Biology Computer science
Chromosome
Histone protein DNA Cancidate solving
Sets the characteristics of an individual in encoded form
mostly more chromosomes
per individual
mostly only one chromo-
some per individual
Gene
Part of a chromosome A character
Basic unit of heredity which sets a part of the charac-
teristics of an individual
Allel
Peculiaritiy of a gene Value of a character
Per chromosome only one peculiarity of a gene
Locus
Location of a gene Position of a character
In a chromosome at a location only one gene
Phenotype Composite of all character-
istics of on organism
Implementation of a candi-
date solving
Genotype Makeup of a cell, an organ-
ism or an individual
Encoding of a candidate
solving
Generation Population of a organism Ppulation at a momentime
Reproduction Generation of descendants
of one or more organisms
Generation of a chromo-
some of one or more chro-
mosomes
Fitness
Aptitude of an organism Goodness of a candidate
solving
Affects the chances of survival and reproduction
Table 3.1: Terms in biology and computer science by comparison
Genetic algorithms have also been applied in health care, but there are fewer examples
of this type of CDSS than those based on neural networks. However, GAs have proved to
be a helpful aid in the diagnosis of female urinary incontinence[18]. An genetic algorithm




• technique of sampling
• genetic operator
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• parameter
• abort criteria
Research has shown that CDSSs based on pattern recognition and machine learning
approaches may be more accurate than the average clinician in diagnosing the targeted
diseases, many physicians are hesitant to use these CDSSs in their practice because the
reasoning behind them is not transparent.
Most of the systems that are available today involve knowledge-based systems with
rules, guidelines, or other compiled knowledge derived from the medical literature. The
research on the effectiveness of CDSS has come largely from a few institutions where
these systems were developed[2].
Example for GA
Nowadays there are a lot of areas where GAs are used. Exempli gratia for planes’ wings.
With GA the profile of wings gets optimized and tested with a computer simulation.
Generally GAs helps solving NP-hard problems, for example the problem with a delivery
service. The question is: ”What is the best route for the delivery service? “.
Figure 3.3: Schematic example for route planning
To get a good solution it is necessary to create a genetic algorithm which encodes
the solution as n-tuple of figures, where n is the amount of enumerated stations. It is
important that every station exists. The fitess function matches the tuples to the length
of the way, multiplied with -1, so it is maximzed. To change a figure of a tuple is suitable
for a mutation operator. But it is necessary that the tuple will be adapted in a second
position, thereby the solution preserves its significance, because the figure, which is a
station, should occur anywhere in the tuple. With crossover it is also important to take
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care that crossed chromosomes represent valid solutions. For the case this is not, the
crossover should be cancelled. The probability of the mutation and crossover can be
defined through systematic testing. The chromosome with the best fitness at the end of
the algorithm is the solution as the order for the stations.
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4.1 Requirements analysis
The previous chapter described the environment for this work as a general hospital in
Kampala and a health center in Mifumi. To know the workprocesses of the facilities it
is important to see how health professionals work. Hence, why the author went to the
facilities to get an overview of the environment for which the decision support system for
drug interaction was designed. It was necessary for further steps to acquire knowledge
about health system, infrastructure of the existing electronic information system and
work flows in the hospitals and health centers. Also important was to get an impression
of how the system is used by the hospital staff.
Therefore meeting trainings for the staff was important to see how health professionals
work with eHMIS and integrate their work with it into their workflow. Because the elder
generation of Uganda did not raise with computers in school they have problems to work
with them and the work with an electronic information system is often slow.
Another point was the analysis of the environment to know how to design, develope
and integrate the new module into the existing electronic health management informa-
tion system. Because there is no documentation of eHMIS it was necessary to “play”
with the system to know its workflows. The next sections describe the requirements of
a decision support system in Uganda for eHMIS.
The functionalites of a Decision Support System (DSS) depends on both the issues it
should solve and who will use it. In this thesis the focus is on a clinical decision support
system.
1. Add, edit, delete interaction
Every health professional with a specific knowledge of drugs, for example a phar-
macist, must have the possibility to add new interactions to the system because of
new drugs. To edit this interactions ins important because some drugs can change,
for example the amount of an ingredient and that is why there is no interaction
with other drugs anymore. Deleting is only necessary if a health facility stop using
a drug.
2. Show interaction
To assist a health professional in his or her work it is important that the system
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informs him or her if there is an interaction. Possible methods, for example, are:
1) show a message in form of a dialog, 2) in form a writing the message directly
in the window where the physician prescribes drugs and much more.
3. On the fly
To not interrupt health workers in their work flow the messages for an interaction
should be shown on the fly as soon as the health professional choose a drug for
prescribing. Otherwise they need to re-check possible interaction after adding
drugs for prescribing and than delete them, what is time consuming.
4. Log
Logs are useful to create statistics, for example, how often an interaction was
shown, which healt worker was the message shown and, if there are problems with
the patient after taking the drugs, other physicians know which drugs the patient
took and see which interaction with which problems could be.
As described above there are other funtionalities for different decision support systems,
but these are only the most essential requirements for this thesis.
4.2 Technical environment
As in the introduction explained eHMIS is a browser-based system. eHMIS is imple-
mented in PHP and JavaScript, its structure is Model, View, Controller (MVC) compli-
ant. It contains eight main folders which are seperated into subfolders that correspond to
the wards in the hospital and health center (actually implemented wards are: pharmacy,
billing, eye clinic, laboratory, general clinic, outpatient department). The subfolders
also contain PHP files for displaying, logic and other important files for the system.
Figure 4.1: Client-Server-Model[43]
For starting eHMIS a user opens a Browser on his laptop or other workstation and
types in the Uniform Resource Locator (URL) to get to the Login page (logon.php). Via
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Hypertext Transfer Protocol (HTTP) the request is sent. ”logon.php“ will be identified
as a PHP file in the web server and transferred by it to the Hypertext Preprocessor
(PHP) interpreter. After execution of the PHP fragments in the file PHP than transfers
a Hypertext Markup Language (HTML) file to the server. The HTML file now contains
pure HTML code and will be sent back by the server[43]. At the backend a MySQL
database is used for the management of persitent data. The connection is supported by
MyODBC, the object database connectivity interface of MySQL database.
Figure 4.2: Structure of eHMIS
The electronical health information management system is MVC conform. Every part
is seperated and the logic can be extracted as well as the controller to use for example
31
4 Methods and Materials
Java dialogs as view. A software architecture pattern is also useful for keeping track of
a project.
Figure 4.3: Scheme of MVC
4.3 Implementation
To understand the implementation of the decision support system for drug interactions
it is important to know the structure of eHMIS and its database.
4.3.1 Knowledge base
Simon Ndira’s eHMIS has a knowledge base in form of a MySQL database which contains
all relevant information for an electronic medical system. For this thesis only some tables
are needed, some new tables were created.
The original database consisted of 138 tables which are seperated into 12 different
parts, for example patient data or data which are important for diagnosises like one
for the International Statistical Classification of Diseases and Related Health Problems
(ICD-10). For the new module 6 tables were created which contain the different in-
teractions plus tracking for statistical matters. A priority is set for every interaction
because of avoiding the so called over-alerting. Therefore a health professional can set
which interactions with the setted priority he or she wants to see. Interactions are di-
vided into three parts: red, orange and green (prio 1, 2, 3). For the tracking the first
table (ehmis tm5 drug drug interaction) consists of an id, id drug one, id drug two and
a describtion (descr) of the interaction with a priority.
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Figure 4.4: Table ehmis tm5 drug drug interaction
Because of easier differentiation of interactions, different areas got sundry tables. The
next table (ehmis tm5 drug food interaction) contains the interactions of drugs with
food, like alcohol or fruits. To show this interactions is necessary because a lot of
people, also physicians, do not know these type of interactions. Columns of this table
are: id, id drug one, food and a describtion (descr) as well as a priority.
Figure 4.5: Table ehmis tm5 drug food interaction
For drug to condition interactions the module gets information about patient’s con-
dition from other tables already existed, but interactions are saved in an extra ta-
ble (ehmis tm5 drug condition interaction). It contains an id, an id drug one, condi-
tion type (could be: pregnant, underweight, size of body and so on) and a describtion
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(descr). It is connected to another table called ehmis tm5 condition type, which contains
the describtions of conditions and last a priority.
Figure 4.6: Table ehmis tm5 drug condition interaction connected with ehmis tm5 condition type
Another a table for drug to disease interactions were created (ehmis tm5 drug disease interaction).
The U.S. Food and Drug Administration (FDA) [9] pools drug to disease interactions
and drug to condition interactions. But in this thesis the areas are seperated for a bet-
ter overview. The columns of the table are: id, id drug one, icd code and a describtion
(descr) as well as a priority.
Figure 4.7: Table ehmis tm5 drug disease interaction
Last but not least the tracking of interactions. Therefore 2 additional tables were
created (ehmis tm0 track interactions, ehmis tm0 interaction type). The main table of
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tracking is track interactions. It is connected with the other tables and gets some in-
formation of a patient from the other tables already existing. Containing the type of
interaction, an id of the interaction, patient’s id, the case, a timestamp and priority
as well as boolean and as foreign keys the ids of the other tables needed (information
about the patient, for example the name, prename and id; data of the case, for example
case id; timestamp is the time when a health worker added a drug to the case; prio is the
prioritey of the interaction; type could be drug to drug, drug to food, drug to condition
and drug to disease with an ICD-10 code.) Most data of the interactions are from a
free database called Drugbank[15]. It contains a lot of drugs with possible interactions
and many other fields which are important for bioinformatics and cheminformatics. The
database is supported by David Wishart, Departments of Computing Science & Bio-
logical Sciences, University of Alberta[40] and also by The Metabolomics Innovation
Centre, a Genome Canada-funded core facility serving the scientific community and
industry with world-class expertise and cutting-edge technologies in metabolomics[38].
Figure 4.8: Tables for tracking interactions
35
4 Methods and Materials
4.3.2 Drug interactions
The idea was to implement a system for drug interactions for different areas, described
in the following sections. As stated above the programming language is PHP and
JavaScript. For a better overview, every interaction type is implemented in its own
class. There is no parent class because they are too assorted among themselves.
At the end of this section screenshots will show how eHMIS and the new module look
like.
Drug-to-drug interactions
The class DrugDrugInteraction has eleven variables and three functions: one for in-
serting a new drug-to-drug interaction into the knowledge base (insertDrugDrugInterac-
tion($vluList)), a function called getDrugDrugInteraction() and a magical function, the
so called construct() function which get three variables: $id drug , $last visit , $prio .
Magical functions are predefined functions in PHP and will be executed if a specific
action occurs.
Figure 4.9: UML scheme of class DrugDrugInteraction
The function getDrugDrugInteraction() is only called if a patient already is taken at
minimum one drug, otherwise there could not be any drug-to-drug interaction. In the
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PHP file tm0.medical.interaction.php the function is assigned with Smarty, a template
enginge for PHP. An assigned function is executed but without any return value.
Listing 4.1: Assign a function with smarty
$smarty−>a s s i g n (”DFI” , $ d f i ) ;
After assigning the function it must be displayed. Therefore Smarty’s function void
display(string template, string chache id, string compile id) was used.
Listing 4.2: Display a function with smarty
$content = $smarty−>d i sp l ay
( ’ . / main/ medical /tm0 . medical . i n t e r a c t i o n s . t p l . html ’ ) ;
Figure 4.10: Workflow of calling a drug interaction
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As a template serves the HTML file tm0.medical.interactions.tpl.html. This file only
contains a HTML table with the interaction functions. To execute the file a health
worker must select a drug (here with brand name). After typing in at minimum 3 letters
of the name the system searches all generic names including this letters. Responsible
for this is the function tm0.medical.reg press.tpl.html. After selecting the correct brand
tm0.medical.interactions.tpl.html is executed and the results of interactions are shown
in the browser below the selected drug. For a drug-to-drug interaction only the drug’s
name could be enough but for drug-to-condition the exact brand is needed. This will be
explained in section Drug-condition interaction.
Drug-to-food interactions
The first chapter describes drug-to-food interactions. This section explains the imple-
mentation of this module and shows the needed classes.
This type of interaction is more for patients than for health professionals. In Uganda,
patients often get drugs without a patient information leaflet and the author’s experience
says a lot of Ugandans do not know about interactions between drugs and food. A health
worker can print this information and give it to a patient.
Figure 4.11: UML scheme of class DrugFoodInteraction
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One of the functions, insertDrugFoodInteraction($vluList), is responsible for adding
a new drug-to-food interactions to the knowledge base. Therefore a name of the food
is needed, for example alcohol, a drug with which the food interacts, a priority and
a describtion (this values are saved in the $vluList). The drug id gehts the function
from the system by selecting it in the data base. The variable $lastVisit is saved in a
$SESSION key. $prio for the priority is a setup of a health worker saved in the data
base.
The class DrugFoodInteraction has ten variables and also three functions. By call-
ing the function getDrugFoodInteraciton() the system automatically calls the function
construct() and commits important variables: the drug’s id, id of the last visit and the
priority of which interactions a health worker wants to see.
Drug-to-disease interactions
This type of drug interaction also needs ten variables but five functions. Like the other
modules it has a construct() function, a function for inserting drug-to-disease inter-
action and than three get-functions for a interactionis itself, to get the actual diseases
a patient has and if existing a chronical disease. This module is not completely imple-
mented because the system do not has all impartant data available.
Figure 4.12: UML scheme of class DrugDiseaseInteraction
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Drug-to-condition interactions
This modules is the most complex one. It consists of 25 variables and five functions.
Described in the first chapter a drug-to-condition interaction could vary. There could
be an interaction because of the weight or an existing pregnancy. Therefore all relevant
patient data are needed, for example the weight, height, male or female.
Figure 4.13: UML scheme of class DrugConditiongInteraction
Some drugs, for example Aspirin, could be too strong for a child or an underweight
person, thats why it is necessary to konw which brand a physician want to prescribe.
Paracetamol 600mg is too strong for small childs and a health professional may be do
not know this. This module informs a health worker and says that it is too strong.
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Figure 4.14: Add prescribtion with showing interactions
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Figure 4.15: Main screen for diagnosises and cases 1
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Figure 4.16: Main screen for diagnosises and cases 2
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Figure 4.17: Main screen for diagnosises and cases 3
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5 Discussion
The previous chapters described how the CDSS was designed and implemented: starting
with a describtion of the environment, analysis of the requirements of a clinical decision
support system for drug interactions over other approaches to the implementation of the
system. Now, this chapter discusses the thesis critically.
The present work has set a starting point for a clinical decision support system for
drug interactions. The investigations should indicate that the use of a CDSS for drug




Alerts are shown in the window where a health professional adds drugs. A problem could
be that a physician works fast with the system and may be will overlook a message for an
interaction or ignore it. May be a better solution is to open a new dialog automatically
with all required information so a health worker needs to close that window first before
he or she can work again with eHMIS.
5.1.2 Forget interaction
After showing possible drug interactions there should also be a messaging system if
a physician prescribed drugs notwithstanding they interact. Such a system could be
another list in the window, where all diagnosises and cases are shown, and beside that
list it could be another list with links which open dialogs containing the specific drug
interactions.
5.2 Future Work
The system eHMIS is not complete. Some more modules are needed, for example for a
child ward in a hospital. A very important part is the statistic. UBOS[39] uses District
Health Information System 2 (DHIS2)[5] for managing routine reports in the health
system. DHIS 2 is the simple, flexible and open-source information system with awesome
visualization features including GIS, charts and pivot tables, completely web-based. To
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integrate this system into eHMIS with either Statistical Data and Metadata Exchange
(Health Domain) (SDMX-HD)[33] or Data Exchange Format (DXF)[7]. DHIS2 has
the possibility to create automatically statistical reports. With such reports a country
knows its health system better and can improve it step by step. eHMIS would be the
first electronic medical system in Uganda connected with DHIS2.
In the last chapter, Appendix, there is a list of the Ministry of Health of Uganda, the so
called Essential Medicines and Health Supplies List for Uganda 2012. This enumeration
contains all essential drugs but not that one which are most used. To have a list with
the most used drugs in Uganda could be an advantage because the Ministry of Health
can save money when buying only drugs which are really needed.
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In this Thesis, a clinical decision support system for drug interactions were designed
and implemented. It was important to know the workflow of health professionals in the
hospital as well as in the health center in Mifumi. Together with the eHMIS team the
clinical decision support system for drug interactions were designed and implemented.
To use free and/or cheap tools for the new module was also relevant to eHMIS, because
health facilities in Uganda do not have a lot of money to spend. The basic requirements
to the CDSS are:
• The system should be as cheap as possible or better completely for free,
• intuitive in handling,
• should have an overview for all drug interactions for a patient,
• an overview for all drug interactions,
• platform-independent and
• show critical alerts to health professionals.
On the basis of this requirements the CDSS were built with PHP and JavaScript. Be-
cause the knowledge base in form of a MySQL database already existed a knowledge-
based approach were used with IF...THEN... rules like IF patient is pregnant AND
physician will prescribe a medication which is not good while pregnancy THEN show
alert. The module was integrated in the existing system with all of its workflows, so the
usability is given and health professionals do not need to interrupt their workprocesses.
The alerts are shown on the fly if a health worker will prescribe two drugs and they
interact or if a patient’s characteristics are bad with a specific medication, for example
if the patient is a baby and thereby too young for a whole tablet of Paracetamol 500mg.







There are a lot of free databases which contain drug interactions. The problem is most
of them are only online accessable or they are too expensive for the health facilities. To
access such a database online is hard because the internet conncection is very slow, a
physician would need too long to know possible interactions. Another problem with on-
line databases is they do not have other patient data for drug to condittion interactions.
Also as you can see in the requirements, the alerts should be shown on the fly and with
online databases this is not possible.
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7.1 Selected source code
Listing 7.1: Class of DrugDrugInteraction
<?php
e r r o r r e p o r t i n g (E ALL ) ;
c l a s s DrugDrugInteract ion
{
p r i v a t e $ id drug = 0 ;
p r i v a t e $ i d p a t i e n t = −1;
p r i v a t e $ l a s t v i s i t ;
p r i v a t e $pres = PRESC;
p r i v a t e $ddi = DRUGTODRUG;
p r i v a t e $gnrcs = GNRCS;
p r i v a t e $ d i f f = −1;
p r i v a t e $day = −1;
p r i v a t e $pr i o = 1 ;
p r i v a t e $ d e s c r i = ”” ;
p r i v a t e $ f l d L i s t = ” id drug one , id drug two , descr , p r i o ” ;
pub l i c func t i on c o n s t r u c t ( $ id drug , $ l a s t v i s i t , $ p r i o )
{
$th i s−> l a s t v i s i t = $ l a s t v i s i t ;
$ th i s−>i d drug = $ id drug ;
$ th i s−>pr i o = $ p r i o ;
$ th i s−>i d p a t i e n t = $ SESSION [ ’ c l i e n t ’ ] ;
}
pub l i c func t i on inse r tDrugDrugInte rac t i on ( $ v luL i s t )
{




pub l i c func t i on getDrugDrugInteract ion ( )
{
$SQLMedDiff = ”SELECT med , d a t e d i f f ( curdate ( ) , startedOn )
as t i m e d i f f ,
days FROM $th i s−>pres WHERE v i s i t = ’ $th i s−> l a s t v i s i t ’ ” ;
$takenMedis = $GLOBALS[ ’ db’]−> execute ( $SQLMedDiff ) ;
// p r i n t r ( $takenMedis ) ;
// echo ”<br>”;
$SQLInteract ion2 = ” s e l e c t id drug one , id drug two , descr ,
p r i o from $th i s−>ddi where id drug two =
’ $th i s−>id drug ’ or id drug one = ’ $th i s−>id drug ’ ” ;
$ i n t e r a c t i o n 2 = $GLOBALS[ ’ db’]−> execute ( $SQLInteract ion2 ) ;
$SQL1 = ” s e l e c t name from $th i s−>gnrcs where id =
’ $th i s−>id drug ’ ” ;
$mach = $GLOBALS[ ’ db’]−> execute ($SQL1 ) ;
f o r each ( $ i n t e r a c t i o n 2 as $ i n t e r 2 )
{
i f ( $ i n t e r 2 [ ’ pr io ’ ] >= $th i s−>pr i o )
{
$SQL22 = ” s e l e c t name , id from $th i s−>gnrcs
where id = ” . $ i n t e r 2 [ ’ id drug one ’ ] ;
$mach22 = $GLOBALS[ ’ db’]−> execute ($SQL22 ) ;
i f ( $ th i s−>i d drug == $ i n t e r 2 [ ’ id drug one ’ ] )
{
$SQL22 = ” s e l e c t name , id from $th i s−>gnrcs
where id = ” . $ i n t e r 2 [ ’ id drug two ’ ] ;
$mach22 = $GLOBALS[ ’ db’]−> execute ($SQL22 ) ;
// p r i n t r ( $mach22 ) ;
}
f o r each ( $takenMedis as $takenMedi )
{
$th i s−>d i f f = $takenMedi [ ’ t i m e d i f f ’ ] ;





i f ( $ th i s−>d i f f < $th i s−>day && $takenMedi [ ’ med ’ ]
== $mach22 [ 0 ] [ ’ id ’ ] )
{
$th i s−>d e s c r i = $th i s−>d e s c r i . ”There i s an
i n t e r a c t i o n between ” . $mach [ 0 ] [ ’ name ’ ] .
” and ” .
$mach22 [ 0 ] [ ’ name ’ ] . ”:<br>” .
$ i n t e r 2 [ ’ descr ’ ] . ”<br>”;
}
}
catch ( Exception $exc )
{
echo $exc−>getTraceAsStr ing ( ) ;
}
}// fo r each ( $medis as $medi )
}
e l s e
{
//must be de l e t ed
echo ”There i s an i n t e r a c t i o n , but
the p r i o r i t y i s too low . <br>”;
}
}// fo r each ( $ i n t e r a c t i o n 2 as $ i n t e r 2 )
// re turn $th i s−>d e s c r i ;
r e turn $th i s−>d e s c r i ;
}
// check i n t e r a c t i o n o f both s i d e s
$SQLInteract ion2 = ” s e l e c t id drug one , id drug two , desc r from $ddi
where id drug two = ’{$ POST [ ’ gener i c ’ ] } ’ or id drug one =
’{$ POST [ ’ gener i c ’ ] } ’ ” ;
$ i n t e r a c t i o n 2 = $db−>execute ( $SQLInteract ion2 ) ;
$SQL1 = ” s e l e c t name from $gnrcs where id = ’{$ POST [ ’ gener i c ’ ] } ’ ” ;
$mach = $db−>execute ($SQL1 ) ;
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i f ( count ( $ i n t e r a c t i o n 2 ) == 0)
{
// save new drug
}
e l s e
{
f o r each ( $ i n t e r a c t i o n 2 as $ i n t e r 2 )
{
$SQL22 = ” s e l e c t name , id from $gnrcs where id = ” .
$ i n t e r 2 [ ’ id drug one ’ ] ;
$mach22 = $db−>execute ($SQL22 ) ;
i f ($ POST [ ’ gener i c ’ ] == $ i n t e r 2 [ ’ id drug one ’ ] )
{
$SQL22 = ” s e l e c t name , id from $gnrcs where id = ” .
$ i n t e r 2 [ ’ id drug two ’ ] ;
$mach22 = $db−>execute ($SQL22 ) ;
}
f o r each ( $medis as $medi )
{
$ d i f f = $medi [ ’ t i m e d i f f ’ ] ;
$day = $medi [ ’ days ’ ] ;
// echo $medi [ ’ med ’ ] ;
// echo ”<br>” . $mach22 [ 0 ] [ ’ id ’ ] ;
i f ( $ d i f f<$day && $medi [ ’ med ’ ] == $mach22 [ 0 ] [ ’ id ’ ] )
{
echo ”There i s an i n t e r a c t i o n between ” .
$mach [ 0 ] [ ’ name ’ ] . ” and ” . $mach22 [ 0 ] [ ’ name ’ ]
. ”<br>”;
}
}// fo r each ( $medis as $medi )
}// fo r each ( $ i n t e r a c t i o n 2 as $ i n t e r 2 )
}// e l s e ( i f ( count ( $ i n t e r a c t i o n 2 ) == 0))
}
?>











Listing 7.3: PHP file tm0.medical.interactions.php
<?php
$brds = BRANDS;
$brand = $ GET[ ” brand id ” ] ;
$ f l d = ” gnrc ” ;
$ id drug = $ehmis−>fetchById ( $brds , id , $brand , $ f l d ) ;
// $ id drug = $ SESSION [ ’ id drug ’ ] ;
$ l a s t V i s i t = $ SESSION [ ’ l a s t V i s i t ’ ] ;
$p r i o = 0 ;
$dose = 0 ;
$ f requency = 0 ;
$days = 0 ;
$ i d p a t i e n t = −1;
$ i d p r o f = −1;
$yesno = −1;
// i f ( $brand != ’ ’ )
//{
$ i n t e r a c t i o n s d r d i = new DrugDrugInteract ion ( $id drug ,
$ l a s t V i s i t , $pr i o ) ;
$drd i = $ i n t e r a c t i o n s d r d i−>getDrugDrugInteract ion ( ) ;
$ i n t e r a c t i o n s d f i = new DrugFoodInteract ion ( $id drug ,
$ l a s t V i s i t , $pr i o ) ;
$ d f i = $ i n t e r a c t i o n s d f i−>getDrugFoodInteract ion ( ) ;
/∗
$ i n t e r a c t i o n s d c i = new DrugCondi t ionInteract ion ( $id drug ,
$ l a s t V i s i t , $pr io , $brand ) ;
$dc i = $ i n t e r a c t i o n s d c i−>getDrugCond i t ionInte ract ion ( ) ;




$smarty−>a s s i g n (”DFI” , $ d f i ) ;
$smarty−>a s s i g n (”DRDI” , $drd i ) ;
// $smarty−>a s s i g n (”DCI” , $dc i ) ;
$content = $smarty−>d i sp l ay
( ’ . / main/ medical /tm0 . medical . i n t e r a c t i o n s . t p l . html ’ ) ;
e x i t ( ) ;
?>
Listing 7.4: PHP file tm0.medical.serach brands ajax.php
<?php
$gnrc = trim ($ GET [ ’ id ’ ] ) ;
$yes = InUse : : YES;
$cond = ” gnrc = ’{ $gnrc } ’ AND i n u s e = ’{ $yes } ’ ” ;
$opt ions = $ehmis−>f e t c h A l l (BRANDS, ’ id ’ , ’ brand ASC’ , $cond ) ;
$brands = array ( ) ;
f o r each ( $opt ions as $opt ion ) {
$item = new Item ( $opt ion [ ’ id ’ ] ) ;
####### CHECK ITEM AVAILABILITY ############
$stock = new Stock ( $item−>id , $ s ta t i on−>d i s p e n s e s t n ) ;
$stock−>fetchItemTotalQtyInStock ( ) ;
$brands [ ] = array ( ’ value ’ => $item−>id , ’ text ’ => ”{$item−>name}
{$item−>s t r ength } {$item−>form }” ,
’ qty ’ => $stock−>tota lQtyInStock ) ;
}
$smarty−>a s s i g n (” brands ” , $brands ) ;
$smarty−>d i sp l ay ( ” . / main/ medical /tm0 . medical . s earch brands . t p l . html ” ) ;




7.2 Total deaths by cause
Place Name Amount Percent
1 HIV/AIDS 65,762 17.70
2 Influenza & Pneumonia 38,919 10.48
3 Diarrhoeal diseases 37,645 10.13
4 Malaria 32,569 8.77
5 Stroke 15,762 4.24
6 Low Birth Weight 13,801 3.71
7 Coronary Heart Disease 13,569 3.65
8 Birth Trauma 12,869 3.46
9 Violence 11,373 3.06
10 Tuberculosis 9,867 2.66
11 Other Injuries 9,289 2.50
12 Road Traffic Accidents 8,192 2.21
13 Pertussis 6,475 1.74
14 Maternal Conditions 6,453 1.74
15 Diabetes Mellitus 5,967 1.61
16 Meningitis 5,702 1.53
17 Lung Disease 4,948 1.33
18 Poisonings 4,258 1.15
19 Congenital Anomalies 4,106 1.11
20 Measles 4,102 1.10
21 Malnutrition 3,605 0.97
22 Kidney Disease 3,463 0.93
23 Suicide 3,299 0.89
24 Trypanosomiasis 3,201 0.86
25 Hypertension 2,746 0.74
26 Schistosomiasis 2,614 0.70
27 Endocrine Disorders 2,480 0.67
28 Cervical Cancer 2,464 0.66
29 Fires 2,452 0.66
30 Drownings 2,447 0.66
31 Asthma 2,184 0.59
32 Epilepsy 2,133 0.57
33 Inflammatory/Heart 2,038 0.55
34 Lymphomas 1,725 0.46
35 War 1,656 0.45
36 Anaemia 1,627 0.44
37 Oesophagus Cancer 1,465 0.39
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38 Syphilis 1,263 0.34
39 Prostate CancerS 1,249 0.34
40 Liver Disease 1,219 0.33
41 Liver Cancer 1,199 0.32
42 Breast Cancer 1,144 0.31
43 Stomach Cancer 1,120 0.30
44 Peptic Ulcer Disease 1,101 0.30
45 Falls 1,036 0.28
46 Vitamin A Deficiency 946 0.25
47 Alzheimers/Dementia 824 0.22
48 Other Neoplasms 662 0.18
49 Colon-Rectum Cancers 622 0.17
50 Oral Cancer 553 0.15
Table 7.1: Total deaths by cause[11]
7.3 Essential medicines
The following list contains essential medicines and health supplies for Uganda which are
important for this thesis. The original list consists of much more drugs. It is written
and corrected by the Ministry of Health, Republic of Uganda[13]. The first entry is
the medicine’s name, in the brackets is the dosage form, strength, level of use (level of
facility), Vital (V), Essential (E), Necessary (N) (VEN) classification. Levels of facilities
are:
• Blood bank (BB)
• National Referral Hospital(NRH)
• Regional laboratory (RL)
• Regional Referral Hospital (glslRRH)
• Hospital (H)







1.1 General anaesthetics and oxygen
• Etomidate (Injection, 2mg/ml, RR, E)
• Halothane (Liquid for inhalation, 100%, HC IV, V)
• Oxygen (Medical gas, 99.8%, HC IV, V)
1.2 Local anaesthetics
• Bupivacaine (Injection, 0.5%, RR, V)
• Lignocaine (Injection, 2%, HC II, V)
1.3 Preoperative and peri-operative medication
• Atropine (Injection, 1mg/ml, HC IV, V)
• Diazepam (Injection, 5mg/ml, HC IV, V)
2. ANALGESICS, ANTIPYRETICS
2.1 Non-opioids
• Acetylsalicylic acid (Tablet, 300mg, HC II, E)
• Ibuprofen (Tablet, 25mg, HC III, E)
• Paracetamol (Tablet 500mg, HC II, E)
2.2 Medicines used for gout
• Indomethacin (Capsule, 25mg, H, N)
2.3 Opioid analgesics
• Codeine (Tablet, 30mg, HC IV, E)
• Morphine (Oral solution, 10mg/ml, HC III, E)
• Pethidine (Injection, 50mg/ml, HC IV, V)
3. ANTI-ALLERGICS AND MEDICINES USED IN ANAPHYLAXIS
• Cetrizine (Tablet, 10mg, H, N)
• Chlorphenamine maleate (Tablet, 4mg, HC II, E)
• Epinephrine (Injection, 1mg/ml, HC II V)
• Promethazine (Tablet, 25mg, HC II, E)
4. ANTIDOTES
4.1 General antidotes
• Charcoal (Tablet, 250mg, HC II, E)




• Benztropine (Injection, 1mg/ml, H, E)
• Calcium gluconate (Injection, 10%, HC III, E)
• Naloxone (Injection, 400g/ml, NRH, E)
5. ANTIEPILEPTICS AND ANTICONVULSANTS
• Carbamazepine (Tablet, 200mg, HC III, V)
• Clonazepam (Tablet, 2mg, RRH, E)
• Valoproate (Tablet, 100mg, H, N)




• Albendazole (Tablet, 400mg, HC I, V)
• Mebendazole (Tablet, 500mg, HC II, E)
• Paracetamol (Tablet 500mg, HC II, E)
ii. Antischistosomals
• Praziquantel (Tablet, 600mg, HC IV, E)
6.2 Antibacterials
i. Beta-Lactam medicines
• Amoxicillin (Capsule, 500mg, HC II, V)
• Amoxicillin (Tablet, 250mg, HC II, V)
• Azithromycin (Tablet, 250mg, RRH, N)
• Benzylpenicillin (Powder for injection, 600mg, HC III, E)
• Cefixime (Tablet, 200mg, H, N)
• Ceftriaxone (Powder for injection, 1g, HC IV, V)
• Cloxacillin (Powder for injection, 500mg, HC IV, E)
• Vancomycin (Injection, 500mg, RRH, E)
ii. Other antibacterial medicines
• Chloramphenicol (Capsule, 250mg, HC III, V)
• Ciprofloxacin (Tablet, 250mg, HC III, V)
• Cotrimoxazole (Tablet, 125mg, HC II, V)
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• Cotrimoxazole (Tablet, 480mg, HC II, V)
• Doxycycline (Tablet, 100mg, HC II, V)
• Erythromycin (Tablet (scored), 250mg, HC IV, N)
• Gentamicin (Injection, 40mg/ml, HC III, V)
• Metronidazole (Tablet, 200mg, HC II, V)
• Nalidixic acid (Tablet, 500mg, H, N)
• Nitrofurantoin (Tablet, 100mg, HC II, E)
iii. Antileprosy medicines
• Prednisolone (Tablet, 20mg, HC III, E)
• Rifampicin + dapsone (Tablet (blister), 600mg + 100mg, HC III, V)
• Rifampicin + clofazimine + dapsone (Tablet (blister), 600mg + 300mg
+ 100mg, HC III, V)
• Thalidomide (Tablet, 50mg, RRH, N)
6.3 Antifungal medicines
• Amphtericin B (Oral suspension, 100mg/ml, RRH, E)
• Clotrimazole (Pessary, 500mg, HC II, E)
• Griseofulvin (Tablet, 125mg, HC III, N)
• Miconazole (Pessary, 100mg, HC IV, N)
• Nystatin (Pessary, 100,000IU, HC III, E)
6.4 Antiprotozoal medicines
i. Antiamoebic medicines
• Metronidazole (Tablet, 200mg, HC II], V)
• Tinidazole (Tablet, 500mg, H, N)
ii. Antimalarial medicines
• Artemether (Injection, 80mg/ml, HC III, E)
• Artesunate (Injection, 60mg/ml, HC III, V)
• Artesunate (Suppository, 50mg, HC I, V)
• Artesunate + amodiaquine (Tablet, 50mg + 200mg, HC IV, E)
• Chloroquine (Tablet, 155mg, HC IV, E)
• Mefloquine (Tablet, 250mg, RRH, N)
iii. Antitrichomoniasis medicines
• Tinidazole (Tablet, 500mg, RRH, NE)
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iv. Medicines used in totoxoplasmosis
• Clindamycin (Capsule, 150mg, H, E)
• Artesunate (Injection, 150mg/ml, H, E)
6.5 Antiviral medicines
• Aciclovir (Tablet, 200mg, HC IV, E)
7. ANTINEOPLASTIC AND IMMUNOSUPPRESSIVE MEDICINES
• Betamethasone (Injection, 4mg/ml, HC IV, E)
• Prednisolone (Tablet, 5mlg, HC IV, E)
8. IMMUNOLOGICALS
8.1 Immunologicals, diagnostic medicienes
• Tuberculin purified protein derivative (Injection, 100IU/ml, HC IV, N)
8.2 Sera and immunoglobulins
• Anti-D immunoglobulin, human (Injection, 250g/ml, RRH, E)
• Antirabies immunoglobulin, human (Injection, 150IU/ml, H, V)
• Antiscorpionserum (Injection, mixture of Androctonus, Leiurus and Buthus
spp in 10ml vial, RRH, N)
• Antitetanus immunoglobulin, human (Injection, 500IU, HC IV, V)
8.3 Vaccines
i. Vaccines for routine immunisation
• Diphtheria-pertussis-tetanus (Suspension for injection, 25 LF Diph-
theria Toxoid ; 6 LF Tetanus Toxoid ; 10,000 million Borditella Per-
tussis in 20-dose vial (10ml), HC II, V)
• Poliomyelitis vaccine, live attenuated (Oral suspension, 20-dose vial
(2ml), HC II, V)
ii. Vaccines for specific groups of individuals
• Anthrax vaccine (Injection, 0.125ml(anthrax antigens)/0.5ml dose,
RRH, V)
• Hepatitis B vaccine (Intradermal injection, single-dose vial, HC IV,
E)
• Human papilloma virus vaccine (type 16 + type 18 capsid protein)(Injection,
40g/ml + 40/ml, HC II, V)




• Plague vaccine (Injection, Single-dose vial, H, N)
• Yellow fever vaccine, live (Injection, 1,000 LD50 units/0.5ml, H, N)
9. CARDIOVASCULAR MEDICINES
9.1 Angianginal medicines
• Atenolol (Tablet, 100mg, H, V)
• Glyceryl trinitrate (Tablet(sublingual), 500g, H, V)
• Nifedipine (Tablet, 10mg, H, E)
9.2 Antidysrhythmic medicines
• Adenosine (Injection, 3mg/ml, RRH, E)
• Propranolol (Tablet, 40mg, HC IV, E)
9.3 Antihypertensive medicines
• Captopril (Tablet, 100mg, H, E)
• Enalapril (Tablet, 5mg, RRH, N)
• Hydralazine (Tablet, 25mg, RRH, N)
• Lisinopril (Tablet, 10mg, H, N)
• Methyldopa (Tablet, 250mg, HC III, E)
9.4 Medicines used in heart failure
i. Cardiac glycosides
• Digoxin (Tablet, 62.5g, HC IV, E)
• Digoxin (Injection, 250g/ml, H, N)
ii. Medicines used in vascular shock
• Dopamine (Concentrate for IV inf, 40mg/ml, H, E)
• Hydrocortisone sodium succinate (Powder for injection, 100mg, HC
IV, E)
10. MUSCLE RELAXANTS AND CHOLINESTERASE INHIBITORS
• Cisatracurium (Injection, 2mg/ml, H, N)
• Rocuronium (Injection, 10mg/ml, H, E)
11. OPHTHALMOLOGICAL PREPARATIONS
11.1 Antiinfective medicines
• Chloramphenicol (Ophthalmic, 1%, HC II, N)
• Chloramphenicol (Eye drops, 0.50%, HC II, N)
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• Gentamicin (Drops for eye/ear, 0.30%, HC IV, N)
• Povidone (Eye drops, 5%, RRH, E)
• Tetracycline (Eye ointment, 1%, HC II, V)
11.2 Anti-inflammatory medicines
• Betamethasone (Eye drops, 0.10%, HC IV, N)
• Dexamethasone (Eye drops, 0.10%, RRH, E)
• Hydrocortisone (Eye ointment, 0.50%, HC IV, N)
• Prednisolone (Eye drops, 0.5.%, HC IV, E)
• Sodium chromoglycate (Eye drops, 2%, RRH, N)
11.3 Antifungal medicines
• Econazole (Eye drops, 2%, RRH, N)
• Natamycin (Ophthalmic suspension, 5%, RRH, N)
11.4 Antiviral medicines
• Aciclovir (Eye ointment, 3%, HC IV, E)
• Ganciclovir (Ophthalmic gel, 0.15%, RRH, E)
11.5 Local anaesthetics
• Bupivacaine (Injection, 0.5%, H, E)
• Hyaluronidase (Injection(powder for reconstitution), 1,500IU, RRH, E)
12. PSYCHOTHERAPEUTIC MEDICINES
• Amitriptyline (Tablet, 25mg, HC III, V)
• Benzhexol (Tablet, 2mg, HC II, V)
• Carbamazepine (Tablet, 200mg, HC IV, V)
• Chlorpromazine (Tablet, 25mg, HC II, E)
• Diazepam (Tablet, 5mg, HC II, V)
• Fluoxetine (Capsule, 20mg, H, V)
• Haloperidol (Tablet, mg, HC IV, E)
• Imipramine (Tablet, 25mg, HC IV, E)
• Promethazine (Tablet, 25mg, HC II, V)
• Trifouperazine (Tablet, 5mg, H, E)




• Aminophylline (Tablet, 100mg, HC III, N)
• Beclomethasone (Aerosol inhalation, 50g/metered dose inhalation, HC
IV, E)
• Prednisolone (Tablet, 5mg, HC IV, V)
• Salbutamol (Nebuliser solution, 2mg/ml, HC III, V)
13.2 Antitussive medicines
• Codeine (Tablet, 30mg, HC IV, E)
14. VITAMINS AND MINERALS
• Calcium lactate (Tablet, 300mg, HC III, N)
• Phytomenadione(vitamin K1) (Injection, 1mg/ml, HC II, V)
• Retinol(vitamin A) (Capsule, 100,00IU, HC II, E)
• Thiamine (Tablet, 100mg, HC IV, E)
• Vitamin B compound(strong) (B5+B6+B2+B1) (Tablet, 20mg + 2mg + 2mg
+ 5mg, HC IV, N)
15. EAR, NOSE AND OROPHARYNGEAL PREPARATIONS
15.1 Ear preparations
• Betamethasone (Eye/ear drops, 0.10%, H, E)
• Clotrimazole (Solution, 1%, H, E)
• Gentamicin (Ear drops, 0.30%, H, V)
15.2 Nasal preparations
• Beclomethasone (Nasal spray(aqueous suspension), 50g/metered spray,
H, N)
• Ephedrine (Nasal drops, 1%, H, E)
• Lignocaine + epinephrine (Nasal drops, 2% + 1:100,000, RRH, N)
15.3 Oropharyngeal preparations
• Lignocaine (Lozenge, 4%, HC IV, N)
• Miconazole (Oral gel, 24mg/ml(20mg/g), HC IV, N)
16. ANTIRETROVIRAL MEDICINES
16.1 Nucleoside/nucleotide reverse transcriptase inhibitors
• Abacavir (Oral solution, 20mg/ml, HC IV, E)
• Emtricitabine (Capsule, 200mg, HC IV, E)
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• Lamivudine (Tablet, 150mg, Hc IV, N)
• Tenofovir (Tablet, 300mg, HC IV, N)
• Zidovudine (Oral solution, 10mg/ml, HC IV, V)
16.2 Non-nucleoside reverse transcriptase inhibitors
• Efavirenz (Tablet, 600mg, H, V)
• Nevirapine (Tablet, 200mg, H, V)
16.3 Dual fixed dose combinations
• Abacavir + lamivudine (Tablet, 60mg + 30mg, HC IV, E)
• Stavudine + lamivudine (Tablet, 6mg + 30mg, HC IV, V)
• Tenofovir + emtricitabine (Tablet, 300mg + 200mg, HC IV, N)
• Zidovudine + lamivudine (Tablet, 300mg + 150mg, HC IV, V)
16.4 Triple fixed dose combinations
• Stavudine + lamivudine + nevirapine (Dispersible tablet, 12mg + 60mg
+ 100mg, H, V)
• Tenofovir + emtricitabine + efavirenz (Tablet, 300mg + 200mg + 600mg,
HC IV, N)
• Zidovudine + lamivudine + abacavir (Tablet, 300mg + 150mg + 300mg,
RRH, N)
• Zidovudine + lamivudine + nevirapine (Tablet, 300mg + 150mg + 200mg,
HC IV, V)
17. NUTRITION
• Formula 75, (Powder, 75kCal + 0.9g protein/100ml, H, V)
• Ready to use therapeutic-feeds (Paste, 30% full fat milk; 28%sugar; 15%
vegetable oil; 15%peanut butter; 1.6% mineral vitamin mix, HC I, N)
18. HORMONES, OTHER ENDOCRINE MEDICINES AND CONTRA-
CEPTIVES
18.1 Adrenal hormones and synthetic substitues
• Dexamethasone (Tablet, 0.5mg, H, N)
• Hydrocortisone (Powder for injection, 100mg, HC III, V)
• Prednisolone (Tablet, 5mg, HC IV, V)
18.2 Hormonal Contraceptives
• Ethinylestradio + levonorgestrel (Tablet 30g + 150g, HC II, E)
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• Levonorgestrel (Tablet, 750g, HC I, V)
18.3 Insulins and other antidiabetic medicines
• Glibenclamide (Tablet, 5mg, HC IV, V)
• Insulin isophane (Injection, 100IU/ml, HC iV, V)
• Soluble insulin (Injection, 100IU/ml, HC IV, V)
18.4 Thyroid hormones and antihyroid medicines
• Carbimazole (Tablet, 5mg, H V)
• Levothyroxine (Tablet, 100g, H, V)
19. DIURETICS
• Bendrflumethiazide (Tablet, 5mg, HC III, E)
• Furosemide (Injection, 10mg/ml, HC IV, V)
• Spironolactone (Tablet, 50mg, H, N)
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ECGs electrocardiogramss. 25
EEGs electroencephalograms. 25
eHMIS electronic Health Management Information System. 2, 10
EHR Electronic Health Record. 10
EMR Electronic Medical Record. 22
FDA U.S. Food and Drug Administration. 34
GA Generic Algorithms. 25
H Hospital. 56, 57, 59–65
HC I Health centre 1 (community level). 56, 59, 64, 65
HC II Health centre 2 (Enrolled Comprehensive Nurse). 18, 56–60, 62, 63
HC III Health centre 3 (Cinical Officer). 18, 56–59, 61, 63, 65
HC IV Health centre 4 (Medical Officer). 18, 56–65
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Acronyms
HMIS Health Management Information System. 10, 18
HTML Hypertext Markup Language. 31
HTTP Hypertext Transfer Protocol. 31
ICD-10 International Statistical Classification of Diseases and Related Health Problems.
32
MoH Ministry of Health. 17
MVC Model, View, Controller. 30
NRH National Referral Hospitals. 17, 56
NSAID Non-steroidal anti-inﬄammatory drugs. 15
OPD Outpatient department. 10
PHP Private Hospitals. 17
PHP Hypertext Preprocessor. 31
PNFP Private Not For Profit. 17
RL Regional laboratory. 56
RRH Regional Referral Hospitals. 17, 58–64
SDMX-HD Statistical Data and Metadata Exchange (Health Domain). 46
UBOS Uganda Bureau Of Statistics. 17, 45
URL Uniform Resource Locator. 30
VEN Vital (V), Essential (E), Necessary (N). 56
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